Oncology - What's the Big Elephant in the Room?

electinib consistently beating crosatinib with hazard ratios anywhere from 0.22 to 0.43 very high response rates we've gone to alto and l dr kamage was lead author on this study. here we saw significant improvement in progression free survival with a hazard ratio of 0.43 I should add that anytime you're talking about these studies depending on whether you're focusing on investigator assessment versus blinded independent review the numbers may vary a little bit some of these studies stopped blinded independent reviews so we're just left with investigator assessment.